Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (GAIN)
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection
versus immediate radical liver resection alone with or without adjuvant chemotherapy in
incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of
radical resection of BTC (ICC/ECC)
The aim of the study is to investigate whether induction chemotherapy followed by radical
re-resection (and - if possible - postoperative chemotherapy) in incidental gallbladder
carcinoma (IGBC) or in front radical resection in biliary tract cancer (BTC) (intrahepatic
cholangiocarcinoma (ICC)/ extrahepatic cholangiocarcinoma (ECC)) prolongs overall survival
without impaired quality of life compared to immediate radical surgery alone with or without
adjuvant chemotherapy (investigator's choice) in patients with IGBC, or BTC (ICC/ECC). One of
the most important secondary objectives is to raise awareness for the necessity of a radical
second surgery as well as to improve the adherence to the treatment guidelines in IGBC.
Further secondary objectives are safety and tolerability of the treatment as well as quality
Incidental Gallbladder Carcinoma, Biliary Tract Cancer
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.